Quantitative computed tomography measurements of bone mineral density prepubertal children with congenital hypothyroidism treated with L-thyroxine

Low bone density (BD) has been reported in patients with hyperthyroidism. Whether or not levothyroxine (LT₄) therapy in children with congenital hypothyroidism (CH) affects BD is unclear. Medical records of 45 patients with various etiologies of CH who had at least one BD measurement (32 female, mean age 7.6 ± 2.6 years) were reviewed. The mean LT₄ dose was 3.6 ± 0.88 μ g/kg/day. Cancellous bone density (CaBD) was measured by quantitative computed tomography (CT) in all 45 patients and 20 had measurements of cortical bone density (CoBD), cross-sectional area (CSA) and cortical bone area (CBA) of the femur. TSH levels were considered partially or completely suppressed when values were <1.0 or <0.5 μIU/ml, respectively. The control group consisted of age- and gender-matched healthy children. No significant differences were found in CaBD, CoBD, CSA, or CBA between patients with CH and controls. There were no significant differences between initial and subsequent BD measurements. No correlations were found between CaBD and etiology of CH, dose or duration of LT₄ therapy, or serum TSH. In pre-pubertal children with CH, LT₄ appears to have no significant effect on BD. Moreover, absence or hypoplasia of the thyroid parenchyma appears to have no significant impact on bone formation within the first 10 years of life.